FrancophonIA/ELRC3.0 huggingface dataset:
English: It is used in patients who have had problems due to blood clots in the past (such as heart disease, a stroke or artery disease) or who have type 2 diabetes that has damaged an organ (such as the eyes, heart or kidneys).
Estonian: Ravimit kasutatakse patsientidel, kellel on olnud trombootilisi tüsistusi (näiteks südamehaigus, infarkt või arterite haigus) või kellel on II tüüpi suhkurtõbi, mis on kahjustanud elundeid (näiteks silmi, südant või neere).
English: The full EPAR for Telmisartan Actavis can be found on the Agency's website EMA website/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Telmisartan Actavise kohta on ameti veebilehel: EMA website/Find medicine/Human medicines/European Public Assessment Reports.
English: By blocking the receptors to which angiotensin II normally attaches, telmisartan stops the hormone having an effect, allowing the blood vessels to widen.
Estonian: Blokeerides retseptorid, mille külge angiotensiin II tavaliselt kinnitub, peatab telmisartaan hormooni toime ja võimaldab veresoontel laieneda.
English: It also allows the heart to pump blood more easily, which can help to reduce the risk of future cardiovascular problems.
Estonian: Samuti võimaldab ravim südamel lihtsamini verd pumbata, mis aitab vähendada kardiovaskulaarsete häirete tekke riski.
English: The doctor should monitor the patient's blood pressure closely when starting Telmisartan Actavis, and may decide to adjust the patient's blood pressure-lowering medication.
Estonian: Arst peab Telmisartan Actavisega ravi alustamisel tähelepanelikult jälgima patsiendi vererõhku ning ta võib otsustada vererõhku vähendavat annust kohandada.
English: pressure is not reached, the dose can be increased to 80 mg, or another medicine for hypertension can be added, such as hydrochlorothiazide.
Estonian: alanda vererõhku soovitud tasemeni, võib annust suurendada 80 mg-ni või täiendada ravi muu kõrgvererõhuravimiga, näiteks hüdroklorotiasiidiga.
English: For more information about treatment with Telmisartan Actavis, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Telmisartan Actavisega toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: For the treatment of essential hypertension, the usual recommended dose of Telmisartan Actavis is 40 mg once a day, but some patients may benefit from using 20 mg once a day.
Estonian: Essentsiaalse hüpertensiooni raviks on tavaline soovitatav Telmisartan Actavise annus 40 mg üks kord ööpäevas, kuid mõnele patsiendile võib piisata ka annusest 20 mg üks kord ööpäevas.
English: The Committee recommended that Telmisartan Actavis be given marketing authorisation.
Estonian: Komitee soovitas anda ravimi Telmisartan Actavis müügiloa.
English: This is a summary of the European public assessment report (EPAR) for Telmisartan Actavis.
Estonian: See on ravimi Telmisartan Actavis Euroopa avaliku hindamisaruande kokkuvõte.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Telmisartan Actavis.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: The active substance in Telmisartan Actavis, telmisartan, is an ‘angiotensin II receptor antagonist', which means that it blocks the action of a hormone in the body called angiotensin II.
Estonian: Telmisartan Actavise toimeaine telmisartaan on angiotensiin II retseptori antagonist, mis blokeerib organismis hormooni angiotensiin II toime.
English: Because Telmisartan Actavis is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Telmisartan Actavis on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: Patients with mild or moderately reduced liver function should not receive doses higher than 40 mg a day.
Estonian: Maksa kerge või mõõduka talitlushäirega patsiendid ei tohi saada suuremaid annuseid kui 40 mg üks kord ööpäevas.
English: The CHMP concluded that, in accordance with EU requirements, Telmisartan Actavis has been shown to have comparable quality and to be bioequivalent to Micardis.
Estonian: Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Telmisartan Actavis võrreldav kvaliteet ja bioekvivalentsus ravimiga Micardis.
English: Because Telmisartan Actavis is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Micardis.
Estonian: Et Telmisartan Actavis on geneeriline ravim, piirdusid uuringud katsetega, milles näidati ravimi bioekvivalentsust võrdlusravimiga Micardis.
English: This means that Telmisartan Actavis is similar to a ‘reference medicine' already authorised in the European Union (EU) called Micardis.
Estonian: See tähendab, et Telmisartan Actavis on sarnane võrdlusravimiga Micardis, millel juba on Euroopa Liidus müügiluba.
English: Telmisartan Actavis is also used to prevent cardiovascular problems (problems with the heart and blood vessels) such as heart attacks or strokes.
Estonian: Telmisartan Actavist kasutatakse ka kardiovaskulaarsete (südame-veresoonkonna) häirete, näiteks infarkti või insuldi ennetamiseks.
English: For the prevention of cardiovascular problems, the recommended dose is 80 mg once a day.
Estonian: Kardiovaskulaarsete häirete ennetamiseks on soovitatav annus 80 mg üks kord ööpäevas.
English: Telmisartan Actavis is used to treat essential hypertension (high blood pressure) in adults.
Estonian: Telmisartan Actavist kasutatakse essentsiaalse hüpertensiooni (kõrgvererõhutõve) raviks täiskasvanutel.
English: Therefore, the CHMP's view was that, as for Micardis, the benefit outweighs the identified risk.
Estonian: Seetõttu on inimravimite komitee arvamusel, et nagu ka Micardise korral, ületab ravimi Telmisartan Activis kasulikkus sellega kaasnevad riskid.
English: Telmisartan Actavis is a medicine that contains the active substance telmisartan.
Estonian: Telmisartan Actavis on ravim, mis sisaldab toimeainena telmisartaani.
English: Telmisartan Actavis is a ‘generic medicine'.
Estonian: Telmisartan Actavis on geneeriline ravim.
English: What are the benefits and risks of Telmisartan Actavis?
Estonian: Milles seisneb Telmisartan Actavise kasulikkus ja mis riskid ravimiga kaasnevad?
English: Why has Telmisartan Actavis been approved?
Estonian: Miks Telmisartan Actavis heaks kiideti?
English: Patients with severely reduced kidney function should receive a lower starting dose of 20 mg once a day.
Estonian: Neeru raske talitlushäirega patsiendid peavad alustama ravi 20 mg annusega üks kord ööpäevas.
English: What is Telmisartan Actavis?
Estonian: Mis on Telmisartan Actavis?
English: Other information about Telmisartan Actavis:
Estonian: Muu teave Telmisartan Actavise kohta
English: How is Telmisartan Actavis used?
Estonian: Kuidas Telmisartan Actavist kasutatakse?
English: How has Telmisartan Actavis been studied?
Estonian: Kuidas Telmisartan Actavist uuriti?
English: What is Telmisartan Actavis used for?
Estonian: Milleks Telmisartan Actavist kasutatakse?
English: How does Telmisartan Actavis work?
Estonian: Kuidas Telmisartan Actavis toimib?
English: MA (EU) Number (Invented) name Strength Pharmaceutical Form Route of Administration
Estonian: Tugevus Ravimvorm
English: 0.6 ml (10 mg/ml) 1 pre-filled syringe
Estonian: 0,6 ml (10 mg/ml)
English: MA (EU) Number
Estonian: Müügiloa nr (Euroopa Liidus)
English: Route of Administration
Estonian: 1 süstel
English: It can make birds more prone to other diseases and can interfere with effective vaccination.
Estonian: See võib muuta linnud muudele haigustele vastuvõtlikumaks ja häirida efektiivset vaktsineerimist.
English: The full EPAR for Innovax-ND-IBD can be found on the Agency's website: ema.europa.eu/medicines/veterinary/EPAR/innovax-nd-ibd.
Estonian: Euroopa avaliku hindamisaruande täistekst Innovax-ND-IBD kohta on ameti veebilehel: ema.europa.eu/medicines/veterinary/EPAR/innovax-nd-ibd.
English: Safety studies have shown that the strain is safe for turkeys, however, precautionary measures must be followed to avoid direct or indirect contact between vaccinated chickens and turkeys.
Estonian: Ohutusuuringutest nähtub, et tüvi on kalkunitele ohutu, kuid siiski tuleb võtta ettevaatusmeetmeid, et vältida vaktsineeritud kanade otsest või kaudset kokkupuudet kalkunitega.
English: Innovax-ND-IBD received a marketing authorisation valid throughout the EU on 22 August 2017.
Estonian: Innovax-ND-IBD müügiluba, mis kehtib kogu Euroopa Liidus, anti 22. augustil 2017.
English: As the vaccine is stored in liquid nitrogen, it is important that any handling is done in a well-ventilated area and that precautions are taken when preparing the vaccine.
Estonian: Et vaktsiini säilitatakse vedelas lämmastikus, on tähtis, et käitlemine toimuks hea ventilatsiooniga kohas ja vaktsiini ettevalmistamisel võetakse ettevaatusmeetmeid.
English: The European Medicines Agency decided that Innovax-ND-IBD's benefits are greater than its risks and recommended it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et vaktsiini Innovax-ND-IBD kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise saab Euroopa Liidus heaks kiita.
English: The vaccine can be given to one-day-old chicks as a single injection under the skin in the neck or directly into 18 - 19-day-old chicken eggs containing embryos (unhatched developing chicks).
Estonian: Vaktsiini saab manustada ühepäevastele tibudele ühekordse subkutaanse süstena kaela piirkonda või otse 18-19 päeva vanustesse embrüoga (koorumata arenevad tibud) munadesse.
English: Vaccinated birds had a protection level of between 81% and 95% against disease signs.
Estonian: Vaktsineeritud lindude kaitsetase haigusnähtude tekke vastu oli 81-95%.
English: For IBD, vaccinated birds were challenged at 3, 4, 6 and 8 weeks after vaccination.
Estonian: Lindude nakkava bursiidi korral nakatati vaktsineeritud linde 3, 4, 6 ja 8 nädalat pärast vaktsineerimist.
English: Other information about Innovax-ND-IBD
Estonian: Muu teave Innovax-ND-IBD kohta
English: ND is a viral infection of chickens which causes gasping and coughing, nervous signs (drooping wings, twisting of the head and neck, circling and paralysis), swelling of the tissues around the eyes and neck, greenish watery diarrhoea and reduced egg production.
Estonian: Newcastle'i haigus (ND) on kanade viirusinfektsioon, mis põhjustab hingeldamist ja köhimist, neuroloogilisi nähte (sorgus tiivad, pea ja kaela kõverdumine, ringliikumine ja halvatus), silmaümbruse ja kaelapiirkonna kudede turset, roheka väljaheitega vesist kõhulahtisust ning munatoodangu vähenemist.
English: Similar challenges were carried out after hatching to show the effects of vaccination of chicken eggs.
Estonian: Sarnaseid nakatamisi tehti pärast koorumist, et tõendada kanamunade vaktsineerimise efektiivsust.
English: IBD, also known as Gumboro disease, is a viral infection of chickens associated with death at 3-6 weeks of age.
Estonian: Lindude nakkav bursiit (IBD) ehk Gumboro haigus on kanade viirusinfektsioon, mida seostatakse surmaga 3-6 nädala vanuses.
English: Safety information has been included in the summary of product characteristics and the package leaflet for Innovax-ND-IBD, including the appropriate precautions to be followed by healthcare professionals and animal owners or keepers.
Estonian: Ravimi omaduste kokkuvõttesse ja pakendi infolehele lisati vaktsiini Innovax-ND-IBD ohutusteave, kus on ka tervishoiuspetsialistide ja loomaomanike või -pidajate võetavad meetmed.
English: For ND, 60% of vaccinated chickens did not develop ND when challenged at 4 weeks after vaccination and 95% of vaccinated chickens were protected 6 weeks after vaccination.
Estonian: 60%-l vaktsineeritud kanadest ei tekkinud Newcastle'i haigust, kui neid nakatati 4 nädalat pärast vaktsineerimist, ning 95%-l vaktsineeritud kanadest püsis kaitse 6 nädalat pärast vaktsineerimist.
English: What is Innovax-ND-IBD and what is it used for?
Estonian: Mis on Innovax-ND-IBD ja milleks seda kasutatakse?
English: In the future if the animals are exposed to similar proteins the immune system will be able to respond more quickly.
Estonian: Kui linnud puutuvad hiljem sarnaste valkudega uuesti kokku, tekivad antikehad kiiremini.
English: The withdrawal period for meat and eggs from chickens treated with Innovax-ND-IBD is ‘zero' days, which means there is no mandatory waiting time.
Estonian: Vaktsiiniga Innovax-ND-IBD vaktsineeritud kanade liha ja munade keeluaeg on 0 päeva, mis tähendab, et keeluaega ei ole.
English: The turkey herpesvirus strain HVP360 has been modified so that it will produce proteins from ND virus and IBD virus.
Estonian: Kalkunite herpesviiruse tüvi HVP360 on modifitseeritud, nii et see toodab ND- ja IBD-viiruse valke.
English: MD is a herpesvirus infection of chickens which can cause paralysis of the wings and legs and causes tumours in various organs.
Estonian: Mareki haigus (MD) on kanade herpesviirusinfektsioon, mis võib põhjustada tiibade ja jalgade halvatust ning põhjustab kasvajate teket eri elundites.
English: Vaccinated chickens were taken from a field study and challenged (brought in contact with the viruses) in the laboratory to show protection after vaccination.
Estonian: Väliuuringus nakatati (lasti kokku puutuda viirustega) vaktsineeritud kanu laboritingimustes, tõendamaks, et vaktsineerimise järel tekib kaitse.
English: Innovax-ND-IBD is a veterinary vaccine used to protect chickens against Newcastle disease (ND), infectious bursal disease (IBD) and Marek's disease (MD).
Estonian: Innovax-ND-IBD on veterinaarvaktsiin, mida kasutatakse kanade kaitsmiseks Newcastle'i haiguse, lindude nakkava bursiidi ja Mareki haiguse eest.
English: An overview of Innovax-ND-IBD and why it is authorised in the EU
Estonian: Innovax-ND-IBD ülevaade ja Euroopa Liidus heakskiitmise põhjused
English: Innovax-ND-IBD is a vaccine containing turkey herpesvirus serotype 3, a type of herpesvirus which does not cause disease in chickens but which is similar to the virus that causes MD.
Estonian: Innovax-ND-IBD on vaktsiin, mis sisaldab kalkuni herpesviiruse serotüüpi 3, mis ei tekita haigust kanadel, kuid sarnaneb Mareki haigust põhjustava viirusega.
English: This overview was last updated in March 2019.
Estonian: Kokkuvõtte viimane uuendus: 03-2019.
English: Innovax-ND-IBD contains a live modified strain of turkey herpesvirus called strain HVP360.
Estonian: Innovax ND-IBD sisaldab kalkunite herpesviiruse modifitseeritud elustüve HVP360.
English: Birds infected with MD virus can be carriers and shedders of the virus for life.
Estonian: MD-viirusega nakatunud linnud võivad viirust kanda ja kõõmaga levitada kogu elu.
English: When Innovax-ND-IBD is given to chickens, the animals' immune system recognises the virus as ‘foreign' and makes antibodies against its proteins.
Estonian: Kui kanadele manustatakse vaktsiini Innovax-ND-IBD, peab lindude immuunsüsteem viirust võõraks ja tekitab selle valkude vastu antikehi.
English: Protection against IBD starts 3 weeks after vaccination and lasts 8 weeks.
Estonian: Kaitse nakkava bursiidi vastu tekib 3 nädalat pärast vaktsineerimist ja püsib 8 nädalat.
English: For MD, 87% of the vaccinated chickens were protected against challenge at 9 days after vaccination.
Estonian: Mareki haiguse korral olid 87% vaktsineeritud kanadest 9 päeva pärast vaktsineerimist kaitstud nakatamise eest.
English: The virus in the vaccine has been modified so that it also makes proteins from ND and IBD viruses.
Estonian: Vaktsiinis sisalduvat viirust on muudetud nii, et see toodab ka Newcastle'i haiguse (ND) ja nakkava bursiidi (IBD) viiruste valke.
English: For MD, 91% of chickens from vaccinated eggs did not develop MD when challenged at 8 days of age.
Estonian: Mareki haigust ei tekkinud 91%-l vaktsineeritud munadest koorunud kanadest pärast nakatamist 8 päeva vanuses.
English: Protection against ND starts 4 weeks after vaccination and lasts 8 weeks.
Estonian: Kaitse Newcastle'i haiguse vastu tekib 4 nädalat pärast vaktsineerimist ja püsib 8 nädalat.
English: How does Innovax-ND-IBD work?
Estonian: Kuidas Innovax-ND-IBD toimib?
English: Protection against MD starts 9 days after vaccination and lasts for life.
Estonian: Kaitse Mareki haiguse vastu tekib 9 päeva pärast vaktsineerimist ja püsib kogu elu.
English: For ND, 92% of chickens from vaccinated eggs did not develop ND when challenged at 46 days after vaccination.
Estonian: 92%-l vaktsineeritud munadest koorunud kanadest ei tekkinud Newcastle'i haigust, kui neid nakatati 46 päeva pärast vaktsineerimist.
English: What are the risks associated with Innovax-ND-IBD?
Estonian: Mis riskid vaktsiiniga Innovax-ND-IBD kaasnevad?
English: How is Innovax-ND-IBD used?
Estonian: Kuidas vaktsiini Innovax-ND-IBD kasutatakse?
English: For IBD, 100% of vaccinated chickens did not develop IBD when challenged at 46 days after vaccination.
Estonian: 100%-l vaktsineeritud kanadest ei tekkinud lindude nakkavat bursiiti, kui neid nakatati 46 päeva pärast vaktsineerimist
English: Since Innovax-ND-IBD is a live vaccine, the vaccine strain can be passed into the environment from vaccinated chickens and may spread to turkeys.
Estonian: Selles sisalduv tüvi võib vaktsineeritud lindudelt keskkonda edasi kanduda ja levida kalkunitele.
English: Innovax-ND-IBD is available as a suspension and solvent to be made into a suspension for injection and can only be obtained with a prescription.
Estonian: Vaktsiini Innovax-ND-IBD turustatakse süstesuspensiooni suspensiooni ja lahustina.
English: This will help protect the chickens against ND, IBD and herpesvirus infections like MD.
Estonian: See aitab kaitsta kanu Newcastle'i haiguse, lindude nakkava bursiidi ja Mareki haiguse eest.
English: What benefits of Innovax-ND-IBD have been shown in studies?
Estonian: Milles seisneb uuringute põhjal vaktsiini Innovax-ND-IBD kasulikkus?
English: List of the names, pharmaceutical form, strength of the medicinal products, route of administration and applicants in the Member States
Estonian: Ravimite nimetuste, ravimivormide, tugevuste, manustamisviiside, taotlejate loetelu liikmesriikides
English: This summary was last updated in 10-2012.
Estonian: Kokkuvõtte viimane uuendus: 10-2012.
English: The full EPAR for Sildenafil Teva can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Sildenafil Teva kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Sildenafil Teva on 30 November 2009.
Estonian: Euroopa Komisjon andis Sildenafil Teva müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 30. novembril 2009.
English: For Sildenafil Teva to be effective, sexual stimulation is required.
Estonian: Et Sildenafil Teva oleks efektiivne, on vaja seksuaalset stimulatsiooni.
English: The recommended dose of Sildenafil Teva is 50 mg taken as needed about one hour before sexual activity.
Estonian: Sildenafil Teva soovitatav annus on 50 mg, mis võetakse vajadusel sisse umbes 1 tund enne suguühet.
English: The maximum recommended dosing frequency is one tablet per day.
Estonian: Ravimi suurim soovitatav annus on 1 tablett ööpäevas.
English: For more information about treatment with Sildenafil Teva, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Sildenafil Tevaga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: This is a summary of the European public assessment report (EPAR) for Sildenafil Teva.
Estonian: See on ravimi Sildenafil Teva Euroopa avaliku hindamisaruande kokkuvõte.
English: Sildenafil Teva is used to treat adult men with erectile dysfunction (sometimes called impotence), when they cannot get or keep a hard penis (erection) sufficient for satisfactory sexual activity.
Estonian: Sildenafil Tevat kasutatakse erektsioonihäirete (impotentsuse) raviks täiskasvanud meestel, kui nad ei suuda saavutada või säilitada rahuldavaks seksuaaleluks vajalikku peenise jäigastumist (erektsiooni).
English: The Committee recommended that Sildenafil Teva be given marketing authorisation.
Estonian: Komitee soovitas anda Sildenafil Teva müügiloa.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Sildenafil Teva.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: Therefore, the CHMP's view was that, as for Viagra, the benefit outweighs the identified risk.
Estonian: Seetõttu arvas inimravimite komitee, et nagu ka Viagra korral, ületab Sildenafil Teva kasulikkus sellega kaasnevad riskid.
English: Because Sildenafil Teva is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Sildenafil Teva on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: Other information about Sildenafil Teva
Estonian: Muu teave Sildenafil Teva kohta
English: The active ingredient in Sildenafil Teva, sildenafil, belongs to a group of medicines called phosphodiesterase type 5 (PDE5) inhibitors.
Estonian: Sildenafil Teva toimeaine sildenafiil kuulub fosfodiesteraas-5 (PDE5) inhibiitorite ravimirühma.
English: The CHMP concluded that, in accordance with EU requirements, Sildenafil Teva has been shown to have comparable quality and to be bioequivalent to Viagra.
Estonian: Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud Sildenafil Teva võrdväärne kvaliteet ja bioekvivalentsus ravimiga Viagra.
English: This means that Sildenafil Teva is similar to a ‘reference medicine' already authorised in the European Union (EU) called Viagra.
Estonian: See tähendab, et Sildenafil Teva on sarnane võrdlusravimiga Viagra, millel juba on Euroopa Liidus müügiluba.
English: Sildenafil Teva sildenafil
Estonian: Sildenafil Teva sildenafiil
English: If Sildenafil Teva is taken with food, the onset of activity may be delayed compared with taking Sildenafil Teva without food.
Estonian: Kui Sildenafil Tevat võetakse koos toiduga, võib ravimi toime avalduda hiljem kui ilma toiduta võtmisel.
English: Sildenafil Teva is a medicine that contains the active substance sildenafil.
Estonian: Sildenafil Teva on ravim, mis sisaldab toimeainena sildenafiili.
English: By blocking the breakdown of cGMP, Sildenafil Teva restores erectile function.
Estonian: cGMP lagundamist blokeerides taastab Sildenafil Teva erektsioonitalitluse.
English: Sildenafil Teva is a ‘generic medicine'.
Estonian: Sildenafil Teva on geneeriline ravim.
English: What is Sildenafil Teva?
Estonian: Mis on Sildenafil Teva?
English: Because Sildenafil Teva is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Viagra.
Estonian: Et Sildenafil Teva on geneeriline ravim, piirdusid patsiendiuuringud katsetega, milles näidati Sildenafil Teva bioekvivalentsust võrdlusravimiga Viagra.
English: kidney problems should start treatment with the 25 mg dose.
Estonian: Maksaprobleemide või raskete neeruprobleemidega patsiendid peavad alustama ravi 25 mg annusega.
English: Why has Sildenafil Teva been approved?
Estonian: Miks Sildenafil Teva heaks kiideti?